NASDAQ:SBPH - Spring Bank Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.45
▲ +0.1 (1.87%)
Get New Spring Bank Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBPH

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Spring Bank Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.45.

This chart shows the closing price for SBPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Spring Bank Pharmaceuticals. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2020B. RileyReiterated RatingHold$2.00Medium
1/29/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$28.00 ➝ $1.50Medium
12/30/2019Piper Jaffray CompaniesLower Price Target$10.00 ➝ $1.70High
12/30/2019B. RileyReiterated RatingBuy ➝ Neutral$16.00 ➝ $2.00Low
12/26/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$10.00 ➝ $10.00High
12/20/2019Cantor FitzgeraldReiterated RatingOverweightHigh
12/11/2019Piper Jaffray CompaniesReiterated RatingBuy$10.00High
8/5/2019B. RileyLower Price TargetBuy$24.00 ➝ $16.00Medium
7/1/2019Piper Jaffray CompaniesLower Price TargetOverweight$25.00 ➝ $10.00High
5/13/2019Dawson JamesReiterated RatingBuyLow
4/12/2019Cantor FitzgeraldSet Price TargetBuy$29.00High
4/12/2019Chardan CapitalSet Price TargetBuy$25.00High
12/7/2018Cantor FitzgeraldSet Price TargetBuy$34.00Low
11/30/2018Chardan CapitalSet Price TargetBuy$45.00High
10/28/2018Chardan CapitalReiterated RatingBuyHigh
10/11/2018Cantor FitzgeraldSet Price TargetBuy$34.00Low
10/9/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$28.00High
10/3/2018Cantor FitzgeraldSet Price TargetBuy$35.00Medium
8/14/2018Piper Jaffray CompaniesInitiated CoverageOverweight$25.00Medium
8/2/2018Cantor FitzgeraldSet Price TargetBuy$35.00High
5/9/2018Cantor FitzgeraldSet Price TargetBuy$32.00Low
2/21/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$29.00 ➝ $32.00Low
11/16/2017Cantor FitzgeraldSet Price TargetBuy$29.00N/A
11/6/2017Chardan CapitalReiterated RatingBuyN/A
11/6/2017B. RileyInitiated CoverageBuy ➝ Buy$30.00N/A
9/17/2017Chardan CapitalReiterated RatingBuyLow
8/7/2017Dawson JamesReiterated RatingBuyLow
8/1/2017Chardan CapitalLower Price TargetBuy ➝ Buy$34.00 ➝ $30.00High
7/19/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$29.00High
5/24/2017Chardan CapitalBoost Price TargetBuy ➝ Buy$16.50 ➝ $34.00High
5/19/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Market Perform$20.00Medium
5/1/2017Chardan CapitalInitiated CoverageBuy ➝ Buy$16.50High
(Data available from 11/27/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Spring Bank Pharmaceuticals logo
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.
Read More

Today's Range

Now: $5.45
Low: $5.23
High: $5.70

50 Day Range

MA: $8.00
Low: $1.21
High: $10.39

52 Week Range

Now: $5.45
Low: $0.80
High: $4.80

Volume

344,000 shs

Average Volume

177,606 shs

Market Capitalization

$94.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Spring Bank Pharmaceuticals?

The following Wall Street research analysts have issued research reports on Spring Bank Pharmaceuticals in the last year:
View the latest analyst ratings for SBPH.

What is the current price target for Spring Bank Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Spring Bank Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Spring Bank Pharmaceuticals in the next year.
View the latest price targets for SBPH.

What is the current consensus analyst rating for Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SBPH.

How do I contact Spring Bank Pharmaceuticals' investor relations team?

Spring Bank Pharmaceuticals' physical mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company's listed phone number is 508-473-5993 and its investor relations email address is [email protected] The official website for Spring Bank Pharmaceuticals is www.springbankpharm.com.